VTVT vTv Therapeutics Inc.

+0.01  (+0%)
Previous Close 2.37
Open 2.41
Price To Book -2.4
Market Cap 105330477
Shares 44,256,503
Volume 89,292
Short Ratio
Av. Daily Volume 2,809,093

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due early 2019.
Type 1 Diabetes
Phase 2 data released August 2016. Primary endpoint met.
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
Type 2 Diabetes
Phase 3 data both Part A (April 9, 2018) and Part B (June 12, 2018) did not meet endpoints.
Azeliragon - STEADFAST
Mild Alzheimer’s disease

Latest News

  1. Watch These 4 Healthcare Stocks Set the Pace on Friday (1/25/19)
  2. vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
  3. 10 trading lessons for 2019 that we learned from the 2018 stock market selloff
  4. Watch These Top Trending Stocks On Jan. 2, 2019
  5. Biotech Rally Ahead of the Market
  6. 4 Healthcare Stocks That Are Raising Eyebrows
  7. Biotech Companies in the News
  8. 4 Healthcare Stocks Gaining Speed on Friday (12/28/18)
  9. Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's Competitive Landscape
  10. vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
  11. VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
  12. VTv Therapeutics: 3Q Earnings Snapshot
  13. vTv Therapeutics Announces Third Quarter 2018 Results and Update
  14. VTv Therapeutics (VTVT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  15. vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market
  16. vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
  17. Stock Market News Daily Roundup October 17
  18. Today's Research Reports on Trending Tickers: vTv Therapeutics and Johnson & Johnson
  19. vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference